GeneDx Appoints Bryan Dechairo as Chief Operating Officer
GeneDx (Nasdaq: WGS), a leader in advancing health outcomes through genomic insights, has announced the appointment of Bryan Dechairo as Chief Operating Officer (COO), effective immediately. In this newly created role, Dechairo will report to Katherine Stueland, CEO and President, and will join the executive leadership team at GeneDx.
“GeneDx has built a market-leading position in pediatric genetics and has an incredible opportunity to pave the way for the genomics revolution in healthcare today,” said Dechairo. This sentiment reflects the company’s expanding potential within the healthcare genomics space, where it is poised to make significant contributions.
As Chief Operating Officer, Dechairo will oversee several key departments at GeneDx, including Product & Technology, Operations, Medical Affairs, Innovation, and Program Management. His leadership will be vital in driving operational excellence as the company enters its next phase of commercial growth. GeneDx aims to continue expanding its footprint in the genomics sector, and Dechairo’s role is central to that ambition.
“Bryan’s extensive clinical, technical, and operational experience, coupled with his proven ability to lead scalable transformations, will be essential in helping us execute our strategic vision,” said Katherine Stueland, CEO and President of GeneDx. “As we embark on this next phase of growth and scale, I’m confident that Bryan’s leadership will be crucial in delivering impactful genomic insights and improving health outcomes for an ever-growing number of patients and families.”
With over 30 years of experience in the diagnostic and pharmaceutical industries, Dechairo brings a wealth of expertise in driving clinical innovations that result in improved patient outcomes. Before joining GeneDx, he served as President and CEO of Sherlock Biosciences, where he successfully led the company’s transformation from a research-stage start-up to a commercial operation. Dechairo has also held senior leadership positions at several prominent companies, including Pfizer, Myriad Genetics, Assurex, and Medco Health. His impressive career trajectory has equipped him with a deep understanding of both the technical and commercial aspects of healthcare, making him well-suited to guide GeneDx through this crucial phase of growth.
Dechairo holds a Ph.D. in Human Genetics from University College London and a BA in Integrative Biology from the University of California, Berkeley. His background in human genetics and his leadership experience in biotechnology make him a valuable asset to GeneDx as the company seeks to strengthen its leadership in the genomics space.
GeneDx has long been a leader in pediatric genetics and is now broadening its focus to apply its expertise to a wider range of genomic applications. With the increased importance of genomic testing in modern medicine, GeneDx is uniquely positioned to help shape the future of healthcare by leveraging its vast genetic data sets and cutting-edge technologies.
“We are excited to have Bryan on board as we continue to push the boundaries of what’s possible in genomics,” said Stueland. “His expertise in scaling operations will allow us to improve how genomic insights are integrated into patient care, helping physicians provide more accurate diagnoses and personalized treatment plans for patients.”
Dechairo himself is enthusiastic about the opportunities at GeneDx. “GeneDx has built a market-leading position in pediatric genetics,” he said. “It has an incredible opportunity to pave the way for the genomics revolution in healthcare today. With world-class products, advanced AI, and some of the most dynamic minds in the industry, I’m excited to supercharge operational excellence and accelerate profitable growth.”
This approach combines the power of genomic testing with large-scale clinical data to accelerate the move toward precision medicine. The company’s expertise in exome and genome testing, combined with its comprehensive interpretation services, places it at the forefront of personalized healthcare. By leveraging the world’s largest rare disease data sets, it is transforming how healthcare is delivered, providing actionable insights that help inform diagnosis, guide treatment, and advance drug discovery.
With Dechairo’s leadership and vision, GeneDx is poised to continue its path of growth and innovation, leading the way in genomic medicine and setting the stage for even greater advancements in healthcare delivery.
Please find the related post
